The treatment of children with cerebral palsy with Botulinum toxin A injections is well established, safe and effective. However, a standardized injection strategy is still missing and the used dosage has escalated over the years. In the recent past, the recommended dosages in Europe were, however, reduced due to a better understanding of the relationship between dosage, severe side effects and the kind of anesthesia used. To combine safety and efficacy, the trend tends to a lower dosage, but combined with a more specific selection of injected muscles. The treatment of these key-muscles takes into account the best support for motor development to attain each individual motor milestone.
References
[1]
Koman, L.A.; Mooney, J.F., III; Smith, B.; Goodman, A.; Mulvaney, T. Management of cerebral palsy with Botulinum-A toxin: preliminary investigation. J. Pediatr. Orthop.？1993, 13, 489–495, doi:10.1097/01241398-199307000-00013. 8370782
[2]
Molenaers, G.; Desloovere, K.; Fabry, G.; De Cock, P. The effects of quantitative gait assessment and botulinum toxin a on musculoskeletal surgery in children with cerebral palsy. J. Bone Joint Surg. Am.？2006, 88, 161–170.
[3]
Simpson, D.M.; Gracies, J.M.; Graham, H.K.; Miyasaki, J.M.; Naumann, M.; Russman, B.; Simpson, L.L.; So, Y. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): Report of the therapeutics and technology assessment subcommittee of the american academy of neurology. Neurology？2008, 70, 1691–1698.
[4]
SCPE. Prevalence and characteristics of children with cerebral palsy in Europe. Dev. Med. Child Neurol.？2002, 44, 633–640. 12227618
[5]
Rosenbaum, P.L.; Gracies, J.M.; Graham, H.K.; Miyasaki, J.M.; Naumann, M.; Russman, B.; Simpson, L.L.; So, Y. Prognosis for gross motor function in cerebral palsy: creation of motor development curves. JAMA？2002, 288, 1357–1363.
[6]
Crothers, B.; Paine, R.S. The Natural History of Cerebral Palsy; Harvard University: Cambridge, 1959; p. 299.
[7]
Berweck, S.; Heinen, F. Cerebralparese. In Blue Book Botulinumtoxin; Berweck, S., Heinen, F., Eds.; Verlag Hans Huber: Bern, Germany, 2008.
[8]
Lukban, M.B.; Rosales, R.L.; Dressler, D. Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: A summary of evidence. J. Neural. Transm.？2009, 116, 319–331.
Baker, R.; Jasinski, M.; Maciag-Tymecka, I.; Michalowska-Mrozek, J.; Bonikowski, M.; Carr, L.; MacLean, J.; Lin, J.P.; Lynch, B.; Theologis, T.; et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: A randomized, double-blind, placebo-controlled, dose-ranging study. Dev. Med. Child. Neurol.？2002, 44, 666–675. 12418791
[11]
Cosgrove, A.P.; Corry, I.S.; Graham, H.K. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev. Med. Child. Neurol.？1994, 36, 386–396.
[12]
Graham, H.K.; Aoki, K.R.; Autti-Ramo, I.; Boyd, R.N.; Delgado, M.R.; Gaebler-Spira, D.J.; Gormley, M.E.; Guyer, B.M.; Heinen, F.; Holton, A.F.; et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture？2000, 11, 67–79, doi:10.1016/S0966-6362(99)00054-5. 10664488
[13]
Heinen, F.; Molenaers, G.; Fairhurst, C.; Carr, L.J.; Desloovere, K.; Valayer, E.C.; Morel, E.; Papavassiliou, A.S.; Tedroff, K.; Pascual-Pascual, S.I.; et al. European consensus table 2006 on botulinum toxin for children with cerebral palsy. Eur. J. Paediatr. Neurol.？2006, 10, 215–225, doi:10.1016/j.ejpn.2006.08.006. 17097905
[14]
Heinen, F.; Desloovere, K.; Schroeder, A.S.; Berweck, S.; Borggraefe, I.; van Campenhout, A.; Andersen, G.L.; Aydin, R.; Becher, J.G.; Bernert, G.; et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur. J. Paediatr. Neurol.？2010, 14, 45–66, doi:10.1016/j.ejpn.2009.09.005. 19914110
[15]
Ward, A.B. Spasticity treatment with botulinum toxins. J. Neural. Transm.？2008, 115, 607–616.
[16]
Rosenbaum, P.L.; Palisano, R.J.; Bartlett, D.J.; Galuppi, B.E.; Russell, D.J. Development of the Gross Motor Function Classification System for cerebral palsy. Dev. Med. Child Neurol.？2008, 50, 249–253.
[17]
Naidu, K.; Smith, K.; Sheedy, M.; Adair, B.; Yu, X.; Graham, H.K. Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy. Dev. Med. Child Neurol.？2010, 52, 139–144.
[18]
US FDA Administration. Early Communication about an Ongoing Safety Review Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B). Available online: http://www.fda.gov/cder/whatsnew.htm (Accessed on 10 August 2008).
[19]
Crowner, B.E.; Brunstrom, J.E.; Racette, B.A. Iatrogenic botulism due to therapeutic Botulinum toxin A injection in a pediatric patient. Clin. Neuropharmacol.？2007, 30, 310–313.
[20]
Pharmacovigilance, S. Botox und Dysport: Risiko schwerwiegender systemischer UAW bei Kindern mit Zerebralparese. Available online: http://www.swissmedic.ch/suchen/index.html (Accessed on 21 June 2008).
[21]
Graham, H.K. Safety of Botulinum toxin A in cerebral palsy. Toxicon？2008, 51, 1–54.
[22]
Wenger, D.R.; Rang, M. The Art and Practice of Children’s Orthopaedics; Raven: New York, NY, USA, 1993.
[23]
Hagglund, G.; Wagner, P. Development of spasticity with age in a total population of children with cerebral palsy. BMC Musculoskelet. Disord.？2008, 9, 150.
[24]
Hagglund, G.; Andersson, S.; Duppe, H.; Lauge-Pedersen, H.; Nordmark, E.; Westbom, L. Prevention of dislocation of the hip in children with cerebral palsy. The first ten years of a population-based prevention programme. J. Bone Joint Surg. Br.？2005, 87, 95–101, doi:10.2106/JBJS.D.02684.
[25]
Molenaers, G.; Schorkhuber, V.; Fagard, K.; van Campenhout, A.; de Cat, J.; Pauwels, P.; Ortibus, E.; de Cock, P.; Desloovere, K. Long-term use of botulinum toxin type A in children with cerebral palsy: Treatment consistency. Eur. J. Paediatr. Neurol.？2008, 13, 421–429.
[26]
Blackmore, A.M.; Boettcher-Hunt, E.; Jordan, M.; Chan, M.D. A systematic review of the effects of casting on equinus in children with cerebral palsy: An evidence report of the AACPDM. Dev. Med. Child. Neurol.？2007, 49, 781–790.
[27]
Placzek, R. Botulinum toxin A in children with infantile cerebral palsy: Indications and treatment concepts. Orthopade？2010, 39, 23–30.
[28]
Placzek, R. Botulinumtoxin in Orthop？die und Sportmedizin; Placzek, R., Ed.; UNI-MED Verlag AG: Bremen, Germany, 2006.
[29]
Russell, A.; Cotton, E. The Pet？ System and Its Evolution in Britain; Acorn Foundation: London, UK, 1994.
[30]
Russell, D.; Rosenbaum, P.; Gowland, C.; Hardy, S.; Lane, M.; Plews, N.; McGavin, H.; Cadman, D.; Jarvis, S. Gross Motor Function Measure Manual; Gross Motor Measures Group: Toronto, Canada, 1993.
[31]
Wijnhoven, T.M.; de Onis, M.; Onyango, A.W.; Wang, T.; Bjoerneboe, G.E.; Bhandari, N.; Lartey, A.; al Rashidi, B. Assessment of gross motor development in the WHO Multicentre Growth Reference Study. Food Nutr. Bull.？2004, 25, S37–S45.
[32]
Kargo, W.J.; Nitz, D.A. Early skill learning is expressed through selection and tuning of cortically represented muscle synergies. J. Neurosci.？2003, 23, 11255–11269.
[33]
Hikosaka, O.; Nakamura, K.; Sakai, K.; Nakahara, H. Central mechanisms of motor skill learning. Curr. Opin. Neurobiol.？2002, 12, 217–222.
[34]
Maier, M.A.; Armand, J.; Kirkwood, P.A.; Yang, H.W.; Davis, J.N.; Lemon, R.N. Differences in the corticospinal projection from primary motor cortex and supplementary motor area to macaque upper limb motoneurons: an anatomical and electrophysiological study. Cereb. Cortex.？2002, 12, 281–296.
[35]
Jang, S.H.; Cho, S.H.; Kim, Y.H.; Kwon, Y.H.; Byun, W.M.; Lee, S.J.; Park, S.M.; Chang, C.H. Cortical activation changes associated with motor recovery in patients with precentral knob infarct. Neuroreport？2004, 15, 395–399.
[36]
Ward, N.S. Functional reorganization of the cerebral motor system after stroke. Curr. Opin. Neurol.？2004, 17, 725–730.
[37]
Ward, N.S.; Brown, M.M.; Thompson, A.J.; Frackowiak, R.S. Neural correlates of motor recovery after stroke: a longitudinal fMRI study. Brain？2003, 126, 2476–2496.
[38]
Murase, N.; Duque, J.; Mazzocchio, R.; Cohen, L.G. Influence of interhemispheric interactions on motor function in chronic stroke. Ann. Neurol.？2004, 55, 400–409.
[39]
Pidcock, F.S.; Fish, D.E.; Johnson-Greene, D.; Borras, I.; McGready, J.; Silberstein, C.E. Hip migration percentage in children with cerebral palsy treated with botulinum toxin type A. Arch. Phys. Med. Rehabil.？2005, 86, 431–435.
[40]
Pascual-Pascual, S.I.; Pascual-Castroviejo, I. Safety of botulinum toxin type A in children younger than 2 years. Eur. J. Paediatr. Neurol.？2008, 13, 511–515.
[41]
Hagglund, G.; Andersson, S.; Duppe, H.; Lauge-Pedersen, H.; Nordmark, E.; Westbom, L. Prevention of severe contractures might replace multilevel surgery in cerebral palsy: results of a population-based health care programme and new techniques to reduce spasticity. J. Pediatr. Orthop. B？2005, 14, 269–273.
[42]
Siebold, D.; Rickensdorf, S. Neurologische rehabilitation von kindern mit hirnsch？digung im ersten und zweiten lebensjahr—Berliner modell. Praxis der Kinder-Reha？2009, 1, 4–10.
